NASDAQ:VIGL Vigil Neuroscience (VIGL) Stock Price, News & Analysis $3.42 -0.34 (-9.04%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$3.31▼$3.7050-Day Range$2.92▼$4.6552-Week Range$2.47▼$9.24Volume66,979 shsAverage Volume274,299 shsMarket Capitalization$128.54 millionP/E RatioN/ADividend YieldN/APrice Target$16.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Vigil Neuroscience alerts: Email Address Vigil Neuroscience MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside385.4% Upside$16.60 Price TargetShort InterestHealthy4.71% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.15) to ($2.03) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.85 out of 5 starsMedical Sector573rd out of 910 stocksBiological Products, Except Diagnostic Industry92nd out of 155 stocks 3.3 Analyst's Opinion Consensus RatingVigil Neuroscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageVigil Neuroscience has only been the subject of 3 research reports in the past 90 days.Read more about Vigil Neuroscience's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.71% of the float of Vigil Neuroscience has been sold short.Short Interest Ratio / Days to CoverVigil Neuroscience has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vigil Neuroscience has recently increased by 1.71%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldVigil Neuroscience does not currently pay a dividend.Dividend GrowthVigil Neuroscience does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VIGL. Previous Next 0.0 News and Social Media Coverage MarketBeat FollowsOnly 1 people have added Vigil Neuroscience to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vigil Neuroscience insiders have not sold or bought any company stock.Percentage Held by Insiders33.03% of the stock of Vigil Neuroscience is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions83.64% of the stock of Vigil Neuroscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vigil Neuroscience's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Vigil Neuroscience are expected to grow in the coming year, from ($2.15) to ($2.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vigil Neuroscience is -1.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vigil Neuroscience is -1.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVigil Neuroscience has a P/B Ratio of 1.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Vigil Neuroscience's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Gold RepublicChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a population of over 1.4 BILLION is “buying gold like there’s no tomorrow,” according to The New York Times. China, a rising global economic threat, aims to reduce its dependence on the US dollar… . Click here now to get your free 'De-Dollarization' Guide. About Vigil Neuroscience Stock (NASDAQ:VIGL)Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.Read More VIGL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VIGL Stock News HeadlinesAugust 29, 2024 | globenewswire.comVigil Neuroscience to Present at Upcoming September Investor ConferencesAugust 23, 2024 | prnewswire.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL)September 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.August 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vigil Neuroscience Inc on Promising Drug Trials and Regulatory ProspectsAugust 13, 2024 | finanznachrichten.deVigil Neuroscience, Inc.: Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 13, 2024 | investorplace.comVIGL Stock Earnings: Vigil Neuroscience Beats EPS for Q2 2024August 13, 2024 | globenewswire.comVigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 1, 2024 | finance.yahoo.comVigil Neuroscience Highlights Publication on ALSP Genetic Mutation Prevalence in Neurology GeneticsSeptember 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.July 31, 2024 | stockhouse.comVigil Presents Data on its Small Molecule TREM2 Agonist Program at 2024 Alzheimer's Association International Conference (AAIC)July 26, 2024 | markets.businessinsider.comBuy Rating Affirmed on Vigil Neuroscience’s VG-3927 Based on Positive Phase 1 Results and Strong Industry OutlookJuly 25, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vigil Neuroscience Inc. on Promising VG-3927 Phase 1 Study Results and Alzheimer’s Treatment Market PotentialJuly 25, 2024 | uk.finance.yahoo.comCoinDesk 20 Performance Update: XRP and NEAR Help Push Index UpwardJuly 25, 2024 | markets.businessinsider.comPromising Early Results for Vigil Neuroscience’s VG-3927 Support Strong Buy RatingJuly 25, 2024 | benzinga.comSmall Neurodegenerative Disease-Focused Vigil Neuroscience Says Alzheimer's Candidate Shows Significant Impact On Disease BimarkerJuly 24, 2024 | globenewswire.comVigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer's DiseaseJuly 19, 2024 | markets.businessinsider.comVigil Neuroscience Inc: Promising Drug Development and Potential for Accelerated FDA Approval Drive Buy RatingJuly 18, 2024 | globenewswire.comVigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International ConferenceSee More Headlines Receive VIGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vigil Neuroscience and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today9/07/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:VIGL CUSIPN/A CIK1827087 Webvigilneuro.com Phone857-254-4445FaxN/AEmployees69Year FoundedN/APrice Target and Rating Average Stock Price Target$16.60 High Stock Price Target$23.00 Low Stock Price Target$4.00 Potential Upside/Downside+385.4%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,640,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-76.02% Return on Assets-62.85% Debt Debt-to-Equity RatioN/A Current Ratio8.39 Quick Ratio8.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.15 per share Price / Book1.59Miscellaneous Outstanding Shares37,584,000Free Float25,170,000Market Cap$128.54 million OptionableNot Optionable Beta1.96 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Ivana Magovcevic-Liebisch J.D. (Age 57)Ph.D., President, CEO & Director Comp: $908.25kSharon MoraniSenior Director of Facilities & OperationsDr. David Gray Ph.D. (Age 49)Chief Scientific Officer Ms. Leah GibsonVice President of Investor Relations and Corporate CommunicationsMr. Christopher Verni J.D. (Age 49)General Counsel & Corporate Secretary April Effort M.B.A.M.S., VP & Head of Corporate DevelopmentMr. Evan A. Thackaberry DABT (Age 51)Ph.D., Senior VP & Head of Early Development Christian Mirescu Ph.D.VP & Head of NeuroimmunologyWeeteck Yeo Ph.D.Senior Vice President of Strategic OperationsAndreas Meier M.D.Senior Vice President of Clinical & Medical SciencesMore ExecutivesKey CompetitorsREGENXBIONASDAQ:RGNXProKidneyNASDAQ:PROKAllogene TherapeuticsNASDAQ:ALLOValnevaNASDAQ:VALNPrime MedicineNYSE:PRMEView All CompetitorsInsiders & InstitutionsPoint72 Asset Management L.P.Bought 1,485,000 shares on 8/19/2024Ownership: 3.951%Point72 Asia Singapore Pte. Ltd.Bought 21,854 shares on 8/15/2024Ownership: 0.058%Ensign Peak Advisors IncBought 166,442 shares on 8/13/2024Ownership: 1.051%Renaissance Technologies LLCBought 11,536 shares on 8/9/2024Ownership: 0.190%Acadian Asset Management LLCBought 6,598 shares on 8/6/2024Ownership: 0.018%View All Insider TransactionsView All Institutional Transactions VIGL Stock Analysis - Frequently Asked Questions How have VIGL shares performed this year? Vigil Neuroscience's stock was trading at $3.38 at the beginning of the year. Since then, VIGL shares have increased by 1.2% and is now trading at $3.42. View the best growth stocks for 2024 here. How were Vigil Neuroscience's earnings last quarter? Vigil Neuroscience, Inc. (NASDAQ:VIGL) issued its earnings results on Tuesday, August, 13th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.02. When did Vigil Neuroscience IPO? Vigil Neuroscience (VIGL) raised $112 million in an initial public offering on Friday, January 7th 2022. The company issued 7,000,000 shares at $15.00-$17.00 per share. Who are Vigil Neuroscience's major shareholders? Vigil Neuroscience's top institutional investors include Point72 Asset Management L.P. (3.95%), Ensign Peak Advisors Inc (1.05%), Renaissance Technologies LLC (0.19%) and Point72 Asia Singapore Pte. Ltd. (0.06%). Insiders that own company stock include Ivana Magovcevic-Liebisch, Christopher Verni, Spyros Papapetropoulos and Evan Thackaberry. View institutional ownership trends. How do I buy shares of Vigil Neuroscience? Shares of VIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VIGL) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vigil Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vigil Neuroscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VIGL Stock Alerts